



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

January 12, 2022



Daily Change in COVID-19 Cases, US

January 22, 2020 – January 10, 2022

TOTAL Cases Reported Since 1/22/20

61,732,283

NEW Cases Reported to CDC on 1/10/22

1,406,527

Change in 7-Day Case Average


+47.4%

Current 7-Day Case Average (1/4/22 - 1/10/22)

750,997

Prior 7-Day Case Average (12/28/21 - 1/3/22)

509,446



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – January 09, 2022

Patients Currently Hospitalized with COVID on 1/9/22

127,963

New Admissions on 1/9/22

18,529

Peak in New Admissions (1/7/22)

21,304

Change in 7-Day Average of New Admissions


+32.5%

Current 7-Day Average of New Admissions (1/3/22 - 1/9/22)

19,768

Prior 7-Day Average of New Admissions (12/27/21 - 1/2/22)

14,917



Daily Change in COVID-19 Deaths, US

January 22, 2020 – January 10, 2022

TOTAL Deaths Reported Since 1/22/2020

837,274

NEW Deaths Reported to CDC on 1/10/22

1,896

Change in 7-Day Death Average

+40.4%

Current 7-Day Death Average (1/4/22 - 1/10/22)


1,633

Prior 7-Day Death Average (12/28/21 - 1/3/22)

1,163

Forecasted Total Deaths by 01/22/22





860,000 to 866,000



*7-day averages exclude historical deaths reported retroactively by states



Kaiser Permanente Southern California Data



53% reduction
in risk of symptomatic
hospitalization



74% reduction
in risk of ICU admission



91% reduction
in risk of mortality

Lewnard JA et al. *medRxiv* January 11, 2022



The Omicron “Medicine Cabinet”


- **Up-to-date COVID-19 vaccination prevents severe disease and keeps you out of the hospital**

- **If you do get sick, therapies prevent disease progression and death**



NIH COVID-19 Treatment Guidelines

[COVID19TREATMENTGUIDELINES.NIH.GOV](https://www.covid19treatmentguidelines.nih.gov)



- State-of-the-art guidance for clinicians on the treatment of patients with COVID-19
- Guidelines Panel includes representatives from 6 USG agencies and 42 voting members from 10 professional societies, academia and healthcare systems
- March 24, 2020 – Initial meeting of the Guidelines Panel
- April 21, 2020 – First guideline released
- Since the initial release, 44 updates and 30.3 million page views



Selected COVID-19 Therapeutics

Targeting the virus

- Remdesivir – FDA approved
- Paxlovid – EUA
- Molnupiravir – EUA
- Anti-SARS-CoV-2 monoclonal antibodies – EUA
 - Regeneron (casirivimab + imdevimab)
 - Eli Lilly (bamlanivimab + etesevimab)
 - GSK & Vir (sotrovimab)



Moderating host responses

- Dexamethasone – recommended for hospitalized patients on oxygen
- Tocilizumab (EUA) or baricitinib (EUA) – recommended for certain patients on dexamethasone
- Other immunomodulators – clinical trials
- Anticoagulants – recommended for certain hospitalized patients

Stages of COVID-19 Disease



Targeting the virus

Moderating host responses

Sources: HC Lane; NIH COVID-19 Treatment Guidelines



COVID-19 Therapy for Outpatients

Goals

- Prevent progression to serious disease, thereby reducing visits to urgent care settings, hospitalizations, deaths
- Reduce duration of illness
- Reduce infectivity/transmission
- Minimize stress on healthcare system

****Highest priority should be given to patients with the highest risk of progression to severe disease****



Prioritization of Therapies Amid Omicron Wave for Outpatients with Mild-to-Moderate COVID-19 at High Risk of Disease Progression

	Relative risk reduction for hospitalization or death
Paxlovid (EUA) – 5 days, oral	89%
Sotrovimab (EUA) – single infusion	85%
Remdesivir (off-label) – infusions on 3 days	87%
Molnupiravir (EUA) – 5 days, oral	30%

Source: NIH COVID-19 Treatment Guidelines



Prioritization of Therapies for Outpatients Amid Limited Resources

- **Immunocompromised; unvaccinated at high risk (anyone ≥ 75 years or ≥ 65 with clinical risk factors)**
- **Unvaccinated at increased risk (anyone ≥ 65 years or anyone < 65 with clinical risk factors)**
- **Vaccinated at high risk (priority to non-boosted)**
- **Vaccinated at increased risk (priority to non-boosted)**

COVID-19 Therapies: The Pipeline

- **Numerous Phase 2 and Phase 3 trials of potential COVID-19 therapies active or pending at www.clinicaltrials.gov**
- **Selected agents in late-stage testing**
 - **Antibody products (e.g. monoclonal, polyclonal antibodies)**
 - **Antivirals (e.g. protease inhibitors, polymerase inhibitors)**
 - **Repurposed agents**
 - **Immunomodulators**
 - **Anticoagulants**





News Release

NIH to Launch Public-Private Partnership to Speed COVID-19 Vaccine and Treatment Options

- **The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership will:**
 - Standardize and share preclinical evaluation methods in an open forum
 - Prioritize and accelerate clinical evaluation of therapeutic candidates with near-term potential
 - Maximize clinical trial capacity and effectiveness
 - Advance vaccine development



ACTIV: Therapeutics Trials

- **ACTIV-1: Immune modulators**
- **ACTIV-2: Outpatient monoclonal antibodies and other therapies**
- **ACTIV-3: Inpatient monoclonal antibodies and other therapies**
- **ACTIV-4: Antithrombotics**
- **ACTIV-5: “Big-effect trial”; aims to identify promising COVID-19 treatments for larger clinical trials**
- **ACTIV-6: Outpatient repurposed drugs**

25+ agents tested
>16,000 patients enrolled



Fight Omicron: Today's Takeaways

- **Up-to-date vaccination is essential**

Visit – [vaccines.gov](https://www.vaccines.gov)

Text – your ZIP code to 438829

Call – 1-800-232-0233

- **Therapies and treatment guidelines are available**

[covid19treatmentguidelines.nih.gov](https://www.covid19treatmentguidelines.nih.gov)





THE WHITE HOUSE
WASHINGTON

WH.GOV